Manidipine HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326783

CAS#: 89226-75-5 (HCl)

Description: Manidipine, also known as CV-4093, is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression. In addition, manidipine does not significantly affect norepinephrine levels, suggesting a lack of sympathetic activation. Manidipine has shown antihypertensive efficacy and appears to be well tolerated in adult and elderly patients with mild or moderate essential hypertension.


Price and Availability

Size
Price

200mg
USD 150
2g
USD 750
20g
USD 2950
Size
Price

500mg
USD 250
5g
USD 1250
50g
USD 4650
Size
Price

1g
USD 450
10g
USD 1850

Manidipine HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 326783
Name: Manidipine HCl
CAS#: 89226-75-5 (HCl)
Chemical Formula: C35H40Cl2N4O6
Exact Mass:
Molecular Weight: 683.627
Elemental Analysis: C, 61.49; H, 5.90; Cl, 10.37; N, 8.20; O, 14.04


Related CAS #: 89226-75-5 (HCl)   89226-50-6 (free base)    

Synonym: CV-4093; CV 4093; CV4093; Manidipine HCl

IUPAC/Chemical Name: 3-(2-(4-benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride

InChi Key: JINNGBXKBDUGQT-UHFFFAOYSA-N

InChi Code: InChI=1S/C35H38N4O6.2ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;;/h4-16,23,32-33,36H,17-22H2,1-3H3;2*1H

SMILES Code: O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3.[H]Cl.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
CAS#89226-75-5 (Manidipine HCl);
CAS#89226-50-6 (Manidipine free base).


References

1: Fogari R, Mugellini A, Circelli M, Cremonesi G. Combination delapril/manidipine as antihypertensive therapy in high-risk patients. Clin Drug Investig. 2011;31(7):439-53. doi: 10.2165/11589000-000000000-00000. Review. PubMed PMID: 21627336.

2: Buset Ríos N, Rodríguez Esparragón F, Fernández-Andrade Rodríguez C, Rodríguez Pérez JC. Vascular and metabolic properties of manidipine. Nefrologia. 2011;31(3):268-74. doi: 10.3265/Nefrologia.pre2010.Nov.10643. Epub 2011 Mar 15. Review. English, Spanish. PubMed PMID: 21407275.

3: Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):751-7. doi: 10.1586/erc.10.48. Review. PubMed PMID: 20528630.

4: Buset Ríos N, Rodríguez Esparragón F, Rodríguez Pérez J. [Cardio-metabolic properties of manidipine: beyond lowering arterial pressure?]. Nefrologia. 2009;29(3):203-7. doi: 10.3265/Nefrologia.2009.29.3.5078.en.full. Review. Spanish. PubMed PMID: 19554052.

5: Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs. 2009;9(3):163-76. doi: 10.2165/00129784-200909030-00004. Review. PubMed PMID: 19463022.

6: Martínez Martín FJ. [Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine]. Nefrologia. 2007;27 Suppl 6:26-35. Review. Spanish. PubMed PMID: 18225601.

7: Otero ML. Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag. 2007;3(3):255-63. Review. PubMed PMID: 17703633; PubMed Central PMCID: PMC2293964.

8: Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Rev Cardiovasc Ther. 2007 Mar;5(2):147-59. Review. PubMed PMID: 17338661.

9: Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs. 2005;65 Suppl 2:11-9. Review. PubMed PMID: 16398058.

10: McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64(17):1923-40. Review. PubMed PMID: 15329044.

11: Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs. 2001;61(12):1777-99. Review. PubMed PMID: 11693466.

12: Rodicio JL. Renal effects of calcium antagonists with special reference to manidipine hydrochloride. Blood Press Suppl. 1996;5:10-5. Review. PubMed PMID: 8973787.

13: Nagaoka A. Pharmacologic characteristics of a new calcium antagonist, manidipine: beneficial effects on renal circulation and vascular changes. Am Heart J. 1993 Feb;125(2 Pt 2):560-5. Review. PubMed PMID: 8430600.